Maryam Fouladi

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. doi request reprint A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Neurooncol 114:173-9. 2013
  2. pmc Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study
    Maryam Fouladi
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229, USA
    J Clin Oncol 29:3529-34. 2011
  3. pmc Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 28:3623-9. 2010
  4. pmc Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 28:4221-7. 2010
  5. pmc Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 26:3749-55. 2008
  6. ncbi request reprint Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children
    Alberto Broniscer
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Neurooncol 76:313-9. 2006
  7. doi request reprint A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study
    Trent R Hummel
    Division of Oncology, Cincinnati Children s Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 60:1452-7. 2013
  8. doi request reprint High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors
    Chie Schin Shih
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 112:1345-53. 2008
  9. ncbi request reprint Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma
    Alberto Broniscer
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA
    Cancer 106:1364-71. 2006
  10. ncbi request reprint Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
    Amar Gajjar
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 7:813-20. 2006

Detail Information

Publications44

  1. doi request reprint A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Neurooncol 114:173-9. 2013
    ..Lapatinib was well-tolerated in children with recurrent or CNS malignancies, but did not inhibit target in tumor and had little single agent activity...
  2. pmc Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study
    Maryam Fouladi
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229, USA
    J Clin Oncol 29:3529-34. 2011
    ..To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies...
  3. pmc Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 28:3623-9. 2010
    ....
  4. pmc Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 28:4221-7. 2010
    ....
  5. pmc Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 26:3749-55. 2008
    ....
  6. ncbi request reprint Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children
    Alberto Broniscer
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Neurooncol 76:313-9. 2006
    ..Although the heterogeneity of prognostic factors in our patients made assessment of treatment outcome more difficult, the addition of 6 cycles of temozolomide after radiotherapy did not seem to alter the poor outcome of these patients...
  7. doi request reprint A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study
    Trent R Hummel
    Division of Oncology, Cincinnati Children s Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 60:1452-7. 2013
    ....
  8. doi request reprint High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors
    Chie Schin Shih
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 112:1345-53. 2008
    ..High-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) has been reported to be effective in treating children with recurrent central nervous system (CNS) malignancies...
  9. ncbi request reprint Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma
    Alberto Broniscer
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA
    Cancer 106:1364-71. 2006
    ..In the current study, the authors assessed the characteristics and estimated the cumulative incidence of IH among children with BSG...
  10. ncbi request reprint Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
    Amar Gajjar
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 7:813-20. 2006
    ..We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma...
  11. pmc Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 115:655-64. 2009
    ..The combination of a platinating agent and etoposide has induced responses in various pediatric tumors. The study estimated the maximum tolerated dose (MTD) of an oxaliplatin and etoposide regimen in children with recurrent solid tumors...
  12. ncbi request reprint Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 24:3678-85. 2006
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase inhibitor, depsipeptide, in children with refractory or recurrent solid tumors...
  13. ncbi request reprint Survival and late mortality in long-term survivors of pediatric CNS tumors
    E Brannon Morris
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 25:1532-8. 2007
    ..To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor...
  14. ncbi request reprint Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes
    Christine Fuller
    Department of Pathology, St Jude Children s, Research Hospital, Memphis, TN, USA
    Am J Clin Pathol 126:277-83. 2006
    ..No deletions of INI1 or amplifications of MYC or MYCN were detected. This report adds 2 cases to our experience of PNTANTR and is the first to demonstrate isochromosome 17q, a molecular alteration typical of medulloblastomas...
  15. ncbi request reprint Phase I study of everolimus in pediatric patients with refractory solid tumors
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 25:4806-12. 2007
    ....
  16. doi request reprint Carboplatin-based primary chemotherapy for infants and young children with CNS tumors
    Maryam Fouladi
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Cancer 115:3243-53. 2009
    ..A carboplatin-based chemotherapy regimen was used as primary postoperative therapy in infants with central nervous system (CNS) tumors to limit renal and ototoxicity and to target systemic exposure...
  17. pmc Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS)
    Feng Bai
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2348-52. 2010
    ..Within-day and between-day precisions were<8.6%, and accuracies were 0.7 and 7.1%. This method was applied to the measurement of plasma MK-0752 levels in a Phase I study of pediatric patients with recurrent or refractory brain tumors...
  18. ncbi request reprint Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 107:2291-7. 2006
    ....
  19. ncbi request reprint Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98)
    Alberto Broniscer
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 103:133-9. 2005
    ..The role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting...
  20. pmc Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma
    Trevor McKibbin
    Department of Clinical Pharmacy and Pharmaceutical Sciences, University of Tennessee, TN, USA
    Clin Cancer Res 16:1049-57. 2010
    ....
  21. ncbi request reprint Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7152-60. 2005
    ....
  22. ncbi request reprint White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:4551-60. 2004
    ....
  23. ncbi request reprint A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 110:2535-41. 2007
    ....
  24. ncbi request reprint Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor
    Clinton F Stewart
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:3357-65. 2004
    ....
  25. ncbi request reprint Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy
    Tanya M Tekautz
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    J Clin Oncol 23:1491-9. 2005
    ..To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH)...
  26. ncbi request reprint Ependymoma: new therapeutic approaches including radiation and chemotherapy
    Thomas E Merchant
    Division of Radiation Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Neurooncol 75:287-99. 2005
    ..Future research in the treatment of this tumor, that afflicts fewer than 200 children in the US each year, will focus on molecular biology, clarifying risk factors for tumor control and late effects, and testing novel agents...
  27. ncbi request reprint Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors
    John C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Cancer Chemother Pharmacol 52:435-41. 2003
    ..To construct a population pharmacokinetic model for temozolomide (TMZ), a novel imidazo-tetrazine methylating agent and its metabolites MTIC and AIC in infants and children with primary central nervous system tumors...
  28. ncbi request reprint Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts
    Markos Leggas
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:3000-7. 2002
    ....
  29. ncbi request reprint Histone deacetylase inhibitors in cancer therapy
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Cancer Invest 24:521-7. 2006
  30. doi request reprint Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts
    Kathleen J Helton
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Neurosurg Pediatr 1:270-6. 2008
    ..The authors sought to determine whether DT imaging and white matter tractography could detect axonal degeneration in patients with brainstem tumors...
  31. ncbi request reprint Polar spongioblastoma of the spinal cord: a case report
    Christine Fuller
    Department of Pathology, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA
    Pediatr Dev Pathol 9:75-80. 2006
    ..Discrimination of these rare aggressive lesions from other CNS tumors with focal palisaded architecture is crucial as the treatment and prognosis of the latter may differ significantly...
  32. ncbi request reprint Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo
    Claire Graham
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Clin Cancer Res 12:223-34. 2006
    ..Here, we have evaluated depsipeptide, a natural tetrapeptide HDAC inhibitor, against a panel of pediatric solid tumor models in vivo and evaluated pharmacokinetic and pharmacodynamic variables with tumor sensitivity...
  33. doi request reprint Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor
    Kathleen Dorris
    Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    J Pediatr Hematol Oncol 33:e250-2. 2011
    ....
  34. ncbi request reprint Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 98:1243-52. 2003
    ....
  35. ncbi request reprint Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature
    Kathleen J Helton
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Cancer 101:1445-54. 2004
    ..Medullomyoblastoma (MMB) is a rare cerebellar embryonal neoplasm that occurs almost exclusively in children. It is biphasic by microscopy, containing myoblastic and primitive neuroectodermal components...
  36. ncbi request reprint Survival and functional outcome of children with hypothalamic/chiasmatic tumors
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 97:1084-92. 2003
    ..We evaluated the impact of clinical and neuroimaging parameters and primary therapy on overall (OS) and progression-free (PFS) survival and on neuroendocrine and neurocognitive outcome in children with H and/or C tumors...
  37. ncbi request reprint Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 98:2232-44. 2003
    ..Histologically, it may mimic oligodendroglioma, central neurocytoma, hemangioblastoma, and renal cell carcinoma...
  38. doi request reprint Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies
    Trent R Hummel
    Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Paediatr Drugs 15:29-42. 2013
    ..Further research is required to understand the biology of pediatric gliomas as well as the use of molecularly targeted agents, especially in patients with surgically unresectable tumors...
  39. ncbi request reprint Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS)
    Feng Bai
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 831:169-75. 2006
    ..This method has been used to measure plasma lapatinib concentrations in a Phase I study in children with cancer...
  40. doi request reprint Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas
    Kathleen Dorris
    Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, MLC 7013, 3333 Burnet Ave, Cincinnati, OH, 45229, USA
    J Neurooncol 117:67-76. 2014
    ..In children with non-brainstem HGG, increased TERC and hTERT expression levels are associated with a worse OS, making telomerase a promising potential therapeutic target in pediatric HGG. ..
  41. doi request reprint A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112)
    Patrick A Thompson
    Authors Affiliations Texas Children s Cancer Center and Department of Pediatrics Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas Division of Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Children s Oncology Group, Arcadia Geron Corporation, Menlo Park, California Department of Oncology, Mayo Clinic, Rochester and Department of Pediatrics, Hematology Oncology, University of Minnesota, Minneapolis, Minnesota
    Clin Cancer Res 19:6578-84. 2013
    ..The purpose of this study was to determine the recommended phase II dose of imetelstat in children with recurrent or refractory solid tumors...
  42. doi request reprint Medulloblastoma with melanotic differentiation: case report and review of the literature
    Christine L Phillips
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA
    J Neurooncol 103:759-64. 2011
    ....
  43. ncbi request reprint End-of-life care preferences of pediatric patients with cancer
    Pamela S Hinds
    Division of Nursing Research and Patient Care Services, Department of Hematology Oncology, Palliative and End of Life Care Task Force, and Ethics Committee, St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 23:9146-54. 2005
    ..We identified the preferences of children and adolescents with advanced cancer about their end-of-life care and the factors that influenced their decisions...
  44. ncbi request reprint Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy
    Kristine R Crews
    Departments of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:2202-9. 2002
    ..The purpose of this study was to determine the effect of enzyme-inducing anticonvulsants (EIAs) on the disposition of irinotecan and metabolites in pediatric patients with high-grade glioma...